| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
S1PR1/EDG1 (EC50 < 1 nM)
Vibozilimod targets the sphingosine-1-phosphate receptor 1 (S1PR1/EDG1). It functions as a potent agonist with an EC50 of 0.2 nM. It displays high selectivity for S1PR1 over S1PR2 and S1PR3, which can be associated with serious side effects. Activation of this receptor induces internalization on lymphocytes, preventing their migration from lymph nodes into the bloodstream. |
|---|---|
| ln Vitro |
In vitro, vibozilimod is a potent S1PR1 agonist with an EC50 of 0.2 nM. It demonstrates high selectivity for S1PR1 over other S1P receptor subtypes. The compound's immunomodulatory activity has been characterized in various cellular assays.
|
| ln Vivo |
A Phase I clinical study confirmed the mechanism of action of Vibozilimod by demonstrating its efficacy in reducing lymphocyte counts in healthy individuals . A Phase II trial (SOLARES-PsO-1) was initiated to evaluate its efficacy and safety in 240 participants with moderate-to-severe chronic plaque psoriasis .
In vivo, vibozilimod has immunomodulatory activity and can reduce lymphocyte counts. It has been studied in the context of inflammatory diseases, where it shows potential for reducing excessive immune activation. It demonstrated potential synergy with other mechanisms in inflammatory bowel disease (IBD)-like IL-23 blockade. |
| Enzyme Assay |
The binding affinity and agonist activity of vibozilimod are measured using cell-based functional assays or radioligand binding studies with recombinant S1PR1 protein. EC50 values are determined from dose-response curves in these assays.
|
| Cell Assay |
Cellular activity of vibozilimod is evaluated in S1PR1-expressing cell lines. Receptor activation, internalization, and downstream signaling are assessed. Lymphocyte migration assays are used to confirm functional activity and immunomodulatory effects.
|
| Animal Protocol |
In vivo efficacy of vibozilimod is evaluated in animal models of inflammatory diseases such as psoriasis and atopic dermatitis. Animals are administered the compound orally, and inflammatory responses, lymphocyte counts, and disease severity are monitored.
|
| ADME/Pharmacokinetics |
Vibozilimod has a molecular formula of C29H36ClN3O5 and a molecular weight of 542.07. It is soluble in ethanol (1.7 mg/mL) when pH is adjusted to 5 with HCl. It is stored as a powder at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for vibozilimod indicate that it does not cause severe adverse effects related to cardiac conduction abnormalities observed with other S1P receptor modulators. Comprehensive toxicity profiling has been conducted in preclinical studies to support its clinical development.
|
| References | |
| Additional Infomation |
Vibozilimod is a small-molecule immunomodulator, as indicated by the INN stem "-imod" in its name. This class encompasses agents with either stimulatory, suppressive, or both types of effects on the immune system. Its monoisotopic molecular weight is 541.23 Da.
Vibozilimod is also known as SCD-044. It is an orally active, selective S1PR1 agonist being developed for inflammatory diseases. Clinical studies have demonstrated significant lymphocyte reduction. It is a valuable tool for studying S1PR1-mediated pathways in immunology and inflammation. |
| Molecular Formula |
C29H36CLN3O5
|
|---|---|
| Molecular Weight |
542.0662
|
| Exact Mass |
541.23
|
| Elemental Analysis |
C, 64.26; H, 6.69; Cl, 6.54; N, 7.75; O, 14.76
|
| CAS # |
1403232-33-6
|
| PubChem CID |
66574564
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
38
|
| Complexity |
727
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C([H])=C(C([H])=C([H])C=1C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])C1=NC(C2C([H])=C([H])C(=C([H])C=2[H])C([H])([H])N2C([H])([H])C([H])([H])C(C(=O)O[H])(C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])[H])C([H])([H])C2([H])[H])=NO1
|
| InChi Key |
LIVCREVOSRJFDS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C29H36ClN3O5/c1-20(2)16-23-8-9-24(17-25(23)30)27-31-26(32-38-27)22-6-4-21(5-7-22)18-33-12-10-29(11-13-33,28(34)35)19-37-15-14-36-3/h4-9,17,20H,10-16,18-19H2,1-3H3,(H,34,35)
|
| Chemical Name |
1-[(4-{5-[3-chloro-4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl}phenyl)methyl]-4-[(2-methoxyethoxy)methyl]piperidine-4-carboxylic acid
|
| Synonyms |
Vibozilimod; SCD-044; SCD 044; 1403232-33-6; Vibozilimod [INN]; 0GYJ8CJ1DE; 1-((4-(5-(3-Chloro-4-(2-methylpropyl)phenyl)-1,2,4-oxadiazol-3-yl)phenyl)methyl)-4-((2-methoxyethoxy)methyl)-4-piperidinecarboxylic acid; SCD044;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~1.92 mg/mL (~3.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8448 mL | 9.2239 mL | 18.4478 mL | |
| 5 mM | 0.3690 mL | 1.8448 mL | 3.6896 mL | |
| 10 mM | 0.1845 mL | 0.9224 mL | 1.8448 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
